Paclitaxel

BNF:: 8.1.5
Status:: Do Not Prescribe (DNP), Red
Decision Date:: None

Comments

DO NOT PRESCRIBE (DNP)⁶: NICE TA 362: paclitaxel as albumin-bound nanoparticles with carboplatin for untreated non-small cell lung cancer. (terminated appraisal. Decision date - November 2015)

RED^1,2,3: NICE TA 389: paclitaxel in combination with platinum or as monotherapy is recommended as an option for treating recurrent ovarian cancer. (Decision date - May 2016)

RED^1,2,3:NICE TA476 (replaces TA360) : paclitaxel as albumin-bound nanoparticles (nab-paclitaxel) with gemcitabine for untreated metastatic pancreatic cancer. (Decision date - Oct 2017)

Black Drug Classifications

6: Have NICE guidance that recommends they should not be used

Red Drug Classifications

1: Requiring specialist assessment to enable patient selection, initiation and ongoing treating
2: Requiring long term on-going monitoring of efficacy by a specialist and not suitable for shared care
3: Requiring long term on-going monitoring of toxicity by a specialist (either because of difficulty in recognising side effects or high cost of investigations to identify toxicity)

search again